Thermo Fisher Scientific Releases New CE-IVD Fusion Transcript Kit for Next-Generation Sequencing
CARLSBAD, Calif. – (March 23, 2015) – Thermo Fisher Scientific today announced the release of the CE-IVD Oncomine Solid Tumour Fusion Transcript kit, a key solution designed to aid clinical-decision making and enable highly accurate and reliable multiplexed sequencing of formalin-fixed, paraffin embedded (FFPE) tumor samples.
Marked for in vitro diagnostic use in the European Union, the Oncomine Solid Tumour Fusion Transcript kit for next-generation sequencing (NGS) enables the detection of rearrangements involving the ALK, ROS-1, RET, and NTRK1 genes from as little as 10ng of RNA. The target content, focusing on lung cancer, but potentially applicable to other solid tumors, was verified with leading clinical researchers from the OncoNetwork Consortium spanning 10 different countries and with years of experience in implementing NGS technologies in clinical laboratories.
Genetic rearrangements that cause fusion transcripts are an important and expanding class of actionable biomarkers in cancer. Current approaches to detect numerous variations in a clinical laboratory rely on the use of multiple tests, each designed to detect a different genetic rearrangement. When used in a sequential manner with other required pathology tests, there is a significant risk of the tumor sample being consumed before an actionable variant is uncovered. The new kit overcomes this hurdle with its low RNA sample input requirement of FFPE tissue (10ng extracted nucleic acid per reaction), ultimately providing actionable information to a greater number of patients and beneficial insight that may help guide treatment.
“This latest kit enables our clinical customers to detect multiple genetic rearrangements from each tumor sample,” said Mike Nolan, vice president and general manager of Oncology at Thermo Fisher Scientific. “When used with our previously released CE-IVD Oncomine Solid Tumour DNA kit, mutations can be identified simultaneously with fusion transcripts, all in a single streamlined procedure.”
"The new CE-IVD kits are robust and can be easily implemented into clinical laboratories,” said Jose Costa, from the IPATIMUP Medical Faculty of Porto, Portugal. “The comprehensive content, selected to align with patient prognosis and therapy decision guidance, represents the new generation of genetic tests for colon and lung cancer patients."
"The introduction of these two new CE-IVD products underscores our commitment to help our customers advance cancer care while meeting the evolving local regulatory requirements,” added Nolan. “We will continue expanding our oncology product portfolio to meet the needs of our clinical customers and help move precision medicine forward.”
* The OncoNetwork Consortium members include these researchers:
Pierre Laurent-Puig1, Cecily Vaughn2, Ludovic Lacroix3, Marjolijn Ligtenberg4, Bastiaan Tops4, Christoph Noppen5, Henriette Kurth5, Nicola Normanno6, Aldo Scarpa7, Ian Cree8, Orla Sheils9, Harriet Feilotter10, José Carlos Machado11, Jose Costa11, Kazuto Nishio12
1 Université Paris Descartes, Paris, France
2 ARUP- Institute for Clinical and Experimental Pathology, Utah, USA
3 Institut Gustave Roussy, Paris, France
4 Radboud University Nijmegen Medical Centre, The Netherlands
5 VIOLLIER AG, Basel, Switzerland
6 Centro Ricerche Oncologiche Mercogliano, Avellino, Italy
7 ARC-NET University of Verona, Italy
8 Warwick University Medical School, United Kingdom
9 Trinity College Dublin, Ireland
10 Queen’s University, Ontario Canada
11 IPATIMUP Medical Faculty of Porto, Portugal
12 Faculty of Medicine, Kinki University, Osaka, Japan
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
FOR IMMEDIATE RELEASE
Thermo Fisher Media Contact:
Carlsbad, CA, USA